Biocure Technology Inc.
Biocure Technology Inc.
CSE Index:
NoCurrency:
CAD Biocure Technology Inc. is a biopharmaceutical company, specializing in the development and commercialization of major biosimilar products. Biocure is currently conducting pre-clinical trials of its biosimilar candidates of Interferon Beta 1b, PEG-Filgrastim and Ranibizumab as well as CAR-T Cell Therapy.
Biocure Technology Inc. (CURE.X)
0.04
0.00 (0.00%)
Biocure Technology Inc. (CURE.X)
*Financial charts powered by Quotemedia.com. All right reserved. View the Terms of Use. Data delayed 15 minutes unless indicated.
Bid Size
30,000
Bid Price
0.015
Ask Price
0.04
Ask Size
19,000
Volume
0
Last Price
0.04
Tick
Net Change
Prev Close
0.04
Open
0.00
Day High
0.00
Day Low
0.00
52 Week High
0.315
52 Week Low
0.01
*Note: Bid Size and Ask Size fields are displayed as actual quantities
Bid Size
0
Bid Price
0.00
Ask Price
0.00
Ask Size
0
Volume
0
Last Price
Tick
Net Change
Prev Close
Open
0.00
Day High
0.00
Day Low
0.00
52 Week High
52 Week Low
*Note: Bid Size and Ask Size fields are displayed as actual quantities
Bid Size
30,000
Bid Price
0.015
Ask Price
0.04
Ask Size
19,000
Volume
0
Last Price
0.04
Tick
Net Change
Prev Close
0.04
Open
0.00
Day High
0.00
Day Low
0.00
52 Week High
0.315
52 Week Low
0.01
*Note: Bid Size and Ask Size fields are displayed as actual quantities
Bid Size
0
Bid Price
0.00
Ask Price
0.00
Ask Size
0
Volume
0
Last Price
Tick
Net Change
Prev Close
Open
0.00
Day High
0.00
Day Low
0.00
52 Week High
52 Week Low
*Note: Bid Size and Ask Size fields are displayed as actual quantities
| Bid Broker | Bid Size | Bid Price | Ask Price | Ask Size | Ask Broker |
|---|---|---|---|---|---|
| National Bank Financial Inc. | 30,000 | 0.015 | 0.04 | 2,000 | TD Securities Inc. |
| TD Securities Inc. | 6,000 | 0.01 | 0.04 | 8,000 | National Bank Financial Inc. |
| TD Securities Inc. | 180,000 | 0.01 | 0.04 | 9,000 | National Bank Financial Inc. |
| TD Securities Inc. | 60,000 | 0.005 | 0.045 | 20,000 | TD Securities Inc. |
| 0 | 0.00 | 0.25 | 4,000 | TD Securities Inc. | |
| 0 | 0.00 | 6.00 | 1,000 | TD Securities Inc. | |
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 |
| Bid Broker | Bid Size | Bid Price | Ask Price | Ask Size | Ask Broker |
|---|---|---|---|---|---|
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 | ||
| 0 | 0.00 | 0.00 | 0 |
| Bid Count | Bid Size | Bid Price | Ask Price | Ask Size | Ask Count |
|---|---|---|---|---|---|
| 1 | 30,000 | 0.015 | 0.04 | 19,000 | 3 |
| 2 | 186,000 | 0.01 | 0.045 | 20,000 | 1 |
| 1 | 60,000 | 0.005 | 0.25 | 4,000 | 1 |
| 0 | 0 | 0.00 | 6.00 | 1,000 | 1 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| Bid Count | Bid Size | Bid Price | Ask Price | Ask Size | Ask Count |
|---|---|---|---|---|---|
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| 0 | 0 | 0.00 | 0.00 | 0 | 0 |
| Date/Time | Price | Change | Volume | Buyer | Seller | Venue |
|---|---|---|---|---|---|---|
| Apr 14, 14:30 | 0.04 | 0.00 | 2,000 | National Bank Financial Inc. | National Bank Financial Inc. | CSE |
| Feb 28, 14:30 | 0.025 | -0.015 | 1,000 | National Bank Financial Inc. | National Bank Financial Inc. | CSE |
| Feb 20, 14:30 | 0.025 | -0.015 | 10,000 | Virtu Canada Corp. | National Bank Financial Inc. | CSE |
| Feb 19, 14:30 | 0.02 | -0.02 | 11,000 | TD Securities Inc. | Haywood Securities Inc. | CSE |
| Feb 18, 20:47 | 0.02 | -0.02 | 2,000 | TD Securities Inc. | Haywood Securities Inc. | CSE |
Company Info
Address
300-1055 West Hastings Street
Vancouver, BC V6E 2E9
CanadaPhone
604-609-7146Email
admin@biocuretech.comWebsite
http://www.biocuretech.comListing date
Monday, May 10, 2010Transfer Agent
Computershare Investor Services Inc.Investor Relations
Purple Crown Communications Corp.Email
Julie@purplecrown.caAuditor
DMCL Chartered Professional AccountantsSEDAR Information
Filing Type
Any
News Releases
Management's Discussion & Analysis
Financial Statements
Material Change Report
Timeframe
1 week1 month3 month6 month1 yearAll Time
Biocure Technology Inc.
Date:
May 2, 2024
Biocure Technology Inc.
Date:
May 2, 2024
Biocure Technology Inc.
Date:
Dec 1, 2023
Biocure Technology Inc.
Date:
Nov 16, 2023
Biocure Technology Inc.
Date:
May 16, 2023
Biocure Technology Inc.
Date:
May 16, 2023
Biocure Technology Inc.
Date:
Apr 29, 2022
Biocure Technology Inc.
Date:
Apr 29, 2022
Biocure Technology Inc.
Date:
Jul 22, 2021
Biocure Technology Inc.
Date:
Apr 30, 2021
Biocure Technology Inc.
Date:
Apr 30, 2021
Biocure Technology Inc.
Date:
Nov 27, 2020
Biocure Technology Inc.
Date:
May 13, 2020
Biocure Technology Inc.
Date:
Apr 29, 2020
Biocure Technology Inc.
Date:
Apr 29, 2020
Biocure Technology Inc.
Date:
Jan 9, 2020
Biocure Technology Inc.
Date:
Apr 30, 2019
Biocure Technology Inc.
Date:
Apr 30, 2019
Biocure Technology Inc.
Date:
May 22, 2018
Biocure Technology Inc.
Date:
Apr 30, 2018
Biocure Technology Inc.
Date:
Oct 23, 2017
Biocure Technology Inc.
Date:
Jul 31, 2017
Biocure Technology Inc.
Date:
Jul 31, 2017
Biocure Technology Inc.
Date:
Feb 15, 2017
Biocure Technology Inc.
Date:
Jan 27, 2017
Biocure Technology Inc.
Date:
Dec 23, 2016
Biocure Technology Inc.
Date:
Aug 3, 2016
Biocure Technology Inc.
Date:
Jul 29, 2015
Biocure Technology Inc.
Date:
Jul 29, 2014
Biocure Technology Inc.
Date:
Jul 25, 2013
Biocure Technology Inc.
Date:
Jul 25, 2013
Biocure Technology Inc.
Date:
Jul 31, 2012
Biocure Technology Inc.
Date:
Sep 12, 2011
Biocure Technology Inc.
Date:
Aug 2, 2011
Biocure Technology Inc.
Date:
Apr 18, 2011
Biocure Technology Inc.
Date:
Apr 18, 2011
Biocure Technology Inc.
Date:
Apr 4, 2011
Company Info
Address
300-1055 West Hastings Street
Vancouver, BC V6E 2E9
CanadaPhone
604-609-7146Email
admin@biocuretech.comWebsite
http://www.biocuretech.comListing date
Monday, May 10, 2010Transfer Agent
Computershare Investor Services Inc.Investor Relations
Purple Crown Communications Corp.Email
Julie@purplecrown.caAuditor
DMCL Chartered Professional AccountantsCapitalization
Issued & Outstanding:
10444504Reserved for Issuance:
884059Company Officers
Konstantin Lichtenwald, Chief Financial Officer
Simon Cheng, Chief Executive Officer
News Releases
Bulletins
23/10/2024
2024-1024 – Consolidation - Biocure Technology Inc. (CURE.X)
le 23 octobre/October 2024
Biocure Technology Inc. has announced a consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidated common share for every nine (9) pre-consolidated common shares.
As a result, the outstanding shares of the company will be reduced to approximately 10,444,504 common shares.
The name and symbol will not change.
